Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1993 2
1994 2
1996 3
1997 1
1998 1
1999 1
2000 1
2001 3
2002 3
2003 1
2004 1
2005 2
2006 3
2007 1
2008 1
2011 2
2012 3
2013 1
2015 1
2016 1
2017 3
2018 1
2019 2
2021 2
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial.
Hollander E, Jacob S, Jou R, McNamara N, Sikich L, Tobe R, Smith J, Sanders K, Squassante L, Murtagh L, Gleissl T, Wandel C, Veenstra-VanderWeele J. Hollander E, et al. Among authors: squassante l. JAMA Psychiatry. 2022 Aug 1;79(8):760-769. doi: 10.1001/jamapsychiatry.2022.1717. JAMA Psychiatry. 2022. PMID: 35793101 Free PMC article. Clinical Trial.
A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome.
Goeldner C, Kishnani PS, Skotko BG, Casero JL, Hipp JF, Derks M, Hernandez MC, Khwaja O, Lennon-Chrimes S, Noeldeke J, Pellicer S, Squassante L, Visootsak J, Wandel C, Fontoura P, d'Ardhuy XL; Clematis Study Group. Goeldner C, et al. Among authors: squassante l. J Neurodev Disord. 2022 Feb 5;14(1):10. doi: 10.1186/s11689-022-09418-0. J Neurodev Disord. 2022. PMID: 35123401 Free PMC article. Clinical Trial.
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers.
Derks M, Lennon-Chrimes S, Guenther A, Squassante L, Wandel C, Szczesny P, Paehler A, Kletzl H. Derks M, et al. Among authors: squassante l. Expert Opin Investig Drugs. 2021 Aug;30(8):893-901. doi: 10.1080/13543784.2021.1948009. Epub 2021 Jul 16. Expert Opin Investig Drugs. 2021. PMID: 34176392 Clinical Trial.
Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.
Ratti E, Carpenter DJ, Zamuner S, Fernandes S, Squassante L, Danker-Hopfe H, Archer G, Robertson J, Alexander R, Trist DG, Merlo-Pich E. Ratti E, et al. Among authors: squassante l. Sleep. 2013 Dec 1;36(12):1823-30. doi: 10.5665/sleep.3208. Sleep. 2013. PMID: 24293756 Free PMC article. Clinical Trial.
Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man.
Hipp JF, Knoflach F, Comley R, Ballard TM, Honer M, Trube G, Gasser R, Prinssen E, Wallace TL, Rothfuss A, Knust H, Lennon-Chrimes S, Derks M, Bentley D, Squassante L, Nave S, Nöldeke J, Wandel C, Thomas AW, Hernandez MC. Hipp JF, et al. Among authors: squassante l. Sci Rep. 2021 Apr 8;11(1):7700. doi: 10.1038/s41598-021-87307-7. Sci Rep. 2021. PMID: 33833333 Free PMC article.
Incidence of gallstones in a population of patients with cirrhosis.
Fornari F, Imberti D, Squillante MM, Squassante L, Civardi G, Buscarini E, Cavanna L, Caturelli E, Buscarini L. Fornari F, et al. Among authors: squassante l. J Hepatol. 1994 Jun;20(6):797-801. doi: 10.1016/s0168-8278(05)80152-7. J Hepatol. 1994. PMID: 7930481
A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.
Bolognani F, Del Valle Rubido M, Squassante L, Wandel C, Derks M, Murtagh L, Sevigny J, Khwaja O, Umbricht D, Fontoura P. Bolognani F, et al. Among authors: squassante l. Sci Transl Med. 2019 May 8;11(491):eaat7838. doi: 10.1126/scitranslmed.aat7838. Epub 2019 May 1. Sci Transl Med. 2019. PMID: 31043521 Clinical Trial.
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.
Umbricht D, Del Valle Rubido M, Hollander E, McCracken JT, Shic F, Scahill L, Noeldeke J, Boak L, Khwaja O, Squassante L, Grundschober C, Kletzl H, Fontoura P. Umbricht D, et al. Among authors: squassante l. Neuropsychopharmacology. 2017 Aug;42(9):1924. doi: 10.1038/npp.2017.92. Neuropsychopharmacology. 2017. PMID: 28701745 Free PMC article.
43 results